HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously ...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results